CN115702155A - 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物 - Google Patents

新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物 Download PDF

Info

Publication number
CN115702155A
CN115702155A CN202180042700.5A CN202180042700A CN115702155A CN 115702155 A CN115702155 A CN 115702155A CN 202180042700 A CN202180042700 A CN 202180042700A CN 115702155 A CN115702155 A CN 115702155A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
membered
independently
heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042700.5A
Other languages
English (en)
Inventor
谢雨礼
吴应鸣
樊后兴
钱立晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of CN115702155A publication Critical patent/CN115702155A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种通式(1)所示的化合物及其制备方法，及通式(1)化合物及其各异构体、各晶型、药学上可接受的盐作为CDK2/4抑制剂在抗肿瘤药物制备中的用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202180042700.5A 2020-06-17 2021-06-16 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物 Pending CN115702155A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010557579 2020-06-17
CN2020105575797 2020-06-17
PCT/CN2021/100336 WO2021254384A1 (zh) 2020-06-17 2021-06-16 新型吡啶并[2，3-d]嘧啶-7(8H)-酮衍生物

Publications (1)

Publication Number Publication Date
CN115702155A true CN115702155A (zh) 2023-02-14

Family

ID=79268495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042700.5A Pending CN115702155A (zh) 2020-06-17 2021-06-16 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物

Country Status (2)

Country Link
CN (1) CN115702155A (zh)
WO (1) WO2021254384A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116390921A (zh) * 2021-09-29 2023-07-04 中国医药研究开发中心有限公司 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途
TW202341982A (zh) * 2021-12-24 2023-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｃｄｋ２抑制劑及其用途
WO2024067820A1 (en) * 2022-09-30 2024-04-04 Shenzhen Ionova Life Science Co., Ltd. Tricyclic compounds as cdk inhibitors and methods of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CN109803968A (zh) * 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CN109803968A (zh) * 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂

Also Published As

Publication number Publication date
WO2021254384A1 (zh) 2021-12-23

Similar Documents

Publication Publication Date Title
CN114901661B (zh) 新型K-Ras G12C抑制剂
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
CN115335379B (zh) 含螺环的喹唑啉化合物
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
CN115702155A (zh) 新型吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物
CN113045570A (zh) 含螺环的喹唑啉化合物
CN115867542A (zh) 新型苯并咪唑化合物
CN113943288A (zh) 5,6-二氢吡嗪并[2,3-c]异喹啉化合物
CN116867787A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
EP4159731A1 (en) New pyrazine compound
CN117295743A (zh) 作为Wee-1抑制剂的吡咯并嘧啶衍生物
CN117412971A (zh) 含吡嗪结构的吡咯并嘧啶衍生物
CN117222648A (zh) 作为Wee-1抑制剂的稠环化合物及其制备方法和用途
CN117222649A (zh) 吡咯并嘧啶衍生物及其制备方法和用途
WO2022171126A1 (zh) 作为Wee-1抑制剂的稠环化合物
CN116848118A (zh) 作为Wee-1抑制剂的吡唑并[3,4-d]嘧啶-3-酮衍生物
WO2023016529A1 (zh) 作为atr抑制剂的萘啶衍生物及其制备方法
CN117751123A (zh) 作为Wee-1抑制剂的5-氟-7H-吡咯并[2,3-d]嘧啶类化合物
CN116249702A (zh) 用作dhodh抑制剂的1,2,4-三唑酮衍生物
WO2023083299A1 (zh) 作为hpk1抑制剂的稠环化合物
CN115768775A (zh) Idh突变体抑制剂及其用途
CN118119622A (zh) 作为shp2抑制剂的稠环化合物
CN117616026A (zh) 用作dhodh抑制剂的1,2,4-三唑酮衍生物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination